Emergex Appoints Dr. Anthony Sedgwick as Non-Executive Director
Abingdon, Oxon, UK, 17 June 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, is pleased to announce that Dr. Anthony Sedgwick has been appointed to the Company’s Board as a Non-Executive Director, effective April 2021.
Dr. Sedgwick is an experienced biotech executive, bringing over 40 years of international experience in the sector to Emergex. He was head of anti-inflammatory Biology at Roche between 1986-1990, and after a 2 year period in Marketing at Roche became Global head of Clinical operations until 2002. At Roche, Dr. Sedgwick was responsible for clinical development, leading to the launch of several products including Invirase® and Tamiflu®. He was also a member of the Company’s Global development committee, and on the Board of Roche Products Ltd UK. Dr. Sedgwick has been the Chief Executive Officer of four biotechnology companies, including Cambridge Biotechnology (2002-2005), DanioLabs (2005-2007), Novacta (2007-2011) and Silence Therapeutics (2011-2012), and has held Chairman positions at numerous companies including Plastid AS (2008-2011), ThioLogics (2011-2013) and most recently at Cotton Mouton Diagnostics (2017-2019).
Dr. Sedgwick holds a PhD in Experimental Pathology at St Bartholomew’s Hospital Medical School in London. He is a Fellow of the Royal College of Pathologists and an honorary Professor at Swansea University Medical School.
Dr. Finian Tan, Chairman of Emergex, commented: “I am delighted to welcome Anthony to our Board of Directors. He brings in an extraordinary range of experience from companies across the sector which will be invaluable to Emergex as we progress our novel vaccine candidates towards the clinic.”
Dr. Anthony Sedgwick, added: “Emergex is pioneering unique vaccine technology to address some of the world’s most challenging and immediate infectious disease threats, including COVID-19. I look forward to working with the Board at this exciting time for the Company.”
– Ends –
For further information, please contact:
| Emergex | Consilium Strategic Communications |
| Storme Moore-Thornicroft, Executive Director
Phone: +44 (0) 1235 527589 Email: smt@emergexvaccines.com
Robin Cohen, Director of Business Development Phone: +44 (0) 1235 527589 Email: rc@emergexvaccines.com |
Chris Gardner / Ashley Tapp / Carina Jurs
Phone: +44 (0)20 3709 5700 Email: Emergex@consilium-comms.com
|
About Emergex
Emergex, a biotechnology company headquartered in Abingdon, UK, with an operating subsidiary in Doylestown, Pennsylvania, USA, is pioneering the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response to address some of the world’s most immediate health threats such as COVID-19, Dengue Fever, Zika, Ebola, pandemic flu and serious intra-cellular bacterial infections.
These set-point vaccines modify the initial immune status of recipients in a way that ‘primes’ their immune systems to recognise subsequent infectious agents much like a natural infection would do, preventing an acute or severe manifestation of the disease.
Emergex combines validated technologies together with the very latest scientific insights in immunology and virology to develop its vaccines, including the use of synthetic peptide codes determined on actual infected cells and using a proprietary gold nanoparticle carrier system for programming.
The Company has a growing pipeline of vaccine candidates. The most advanced development programme is a vaccine for Dengue Fever, which may also be disease modifying for other Flaviviruses such as the Zika and Yellow Fever viruses. Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.
Emergex has partnered with the Institute of Molecular and Cell Biology (IMCB) of Singapore to develop a vaccine for the emerging threat of Hand, Foot and Mouth (HFM) disease. The Company also has a collaboration in place with Brazil-based Bio-Manguinhos/Fiocruz for the development of several vaccine candidates, including a potential vaccine for COVID-19.
Find out more online at www.emergexvaccines.com.
